Safety, tolerability and pharmacokinetics of single and multiple doses of a novel sigma-1 receptor antagonist in three randomized phase I studies

被引:56
|
作者
Abadias, Montserrat [1 ]
Escriche, Marisol [2 ]
Vaque, Anna [3 ]
Sust, Mariano [1 ]
Encina, Gregorio [2 ]
机构
[1] ESTEVE Res & Dev, Dept Clin Invest, Barcelona 08041, Spain
[2] ESTEVE Res & Dev, ADME & Bioanal, Barcelona 08041, Spain
[3] ESTEVE Res & Dev, Drug Safety & Pharmacovigilance, Barcelona 08041, Spain
关键词
pain; pharmacodynamics; pharmacokinetics; S1RA (E-52862); safety; tolerability; OPIOID ANALGESIA; PHARMACOLOGY;
D O I
10.1111/j.1365-2125.2012.04333.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT A novel and highly selective sigma-1 receptor antagonist (S1RA) provides a new approach for pain management. S1RA has shown activity in animal models of neuropathic pain and potentiation of opioid analgesia. WHAT THIS STUDY ADDS Phase I studies of single and multiple oral dose administration show that S1RA is safe and well tolerated by healthy subjects. S1RA is rapidly absorbed and its rate and extent of exposure increases with dose. The safety, tolerability, pharmacokinetic and pharmacodynamic profiles of S1RA support its further phase II development in different pain indications. AIM To assess the safety, tolerability, pharmacodynamics and pharmacokinetics in healthy subjects of a novel, highly selective, sigma-1 receptor antagonist (S1RA). METHODS Three randomized, double-blind, placebo-controlled trials evaluated single oral doses (5500 mg, study 101; 500800 mg, study 106) and multiple doses (50400 mg once daily for 8 days, study 102) of S1RA. Safety and tolerability were assessed by adverse event reporting, clinical laboratory, physical examinations, vital signs and electrocardiography, including Holter monitoring. Pharmacodynamic assessments included computerized cognitive testing. Plasma samples were analyzed using validated HPLC-MS/MS methods. RESULTS One hundred and seventy-five subjects were enrolled. Single and multiple doses were safe and well tolerated, with no serious adverse events. The most common side effects were headache and dizziness. The highest single doses were associated with some mild to moderate transient CNS effects. The maximum tolerated dose was not reached. There were no clinically significant changes in the electrocardiogram (ECG), 24 h Holter monitoring, or in vital signs and laboratory assessments. Subjective CNS pharmacodynamics evaluations showed no relevant differences vs. placebo. Cognitive testing showed no effects on visual memory, executive function, attention or somnolence, while revealing some transient slowing of response for simple reaction time and choice reaction time at 2 h following the administration of higher doses. A fast absorption, rapid distribution and slow elimination were observed (tmax 0.752.0 h, t1/2 compatible with once a day administration) and steady-state was reached. No gender differences were observed. CONCLUSIONS S1RA exhibited an acceptable safety, tolerability, pharmacodynamic and pharmacokinetic profile in healthy subjects over the dose range studied.
引用
收藏
页码:103 / 117
页数:15
相关论文
共 50 条
  • [21] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies
    Anthony Cahn
    Ruth Tal-Singer
    Isabelle J. Pouliquen
    Rashmi Mehta
    Andrew Preece
    Kelly Hardes
    Glenn Crater
    Amanda Deans
    Clinical Drug Investigation, 2013, 33 : 477 - 488
  • [22] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Inhaled Doses of Umeclidinium in Healthy Subjects: Two Randomized Studies
    Cahn, Anthony
    Tal-Singer, Ruth
    Pouliquen, Isabelle J.
    Mehta, Rashmi
    Preece, Andrew
    Hardes, Kelly
    Crater, Glenn
    Deans, Amanda
    CLINICAL DRUG INVESTIGATION, 2013, 33 (07) : 477 - 488
  • [23] A safety, tolerability, and pharmacokinetics (PK) study of single and multiple doses of lecozotan sustained release (SR), a novel S-HT1A antagonist, in healthy young subjects
    Raja, S.
    Parks, V.
    Plotka, A.
    Patas, A.
    Paul, J.
    Chalon, S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1121 - 1121
  • [24] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy SubjectsA Randomized, Double-Blind, Placebo-Controlled, Phase I Study
    Michael Derks
    Judith Anzures-Cabrera
    Lynn Turnbull
    Mary Phelan
    Clinical Drug Investigation, 2011, 31 : 325 - 335
  • [25] Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects A Randomized, Double-Blind, Placebo-Controlled, Phase I Study
    Derks, Michael
    Anzures-Cabrera, Judith
    Turnbull, Lynn
    Phelan, Mary
    CLINICAL DRUG INVESTIGATION, 2011, 31 (05) : 325 - 335
  • [26] Safety, tolerability, and pharmacokinetics of single and multiple doses of KNS-760704 in healthy volunteers
    Graham, Cheryl F.
    Mather, James L.
    Ingersoll, Evan W.
    Kramer, William G.
    Hebrank, Gregory T.
    Bozik, Michael E.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1107 - 1107
  • [27] Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers
    Burstein, Aaron H.
    Fullerton, Terence
    Clark, David J.
    Faessel, Helene M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 46 (11): : 1234 - 1240
  • [28] Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults
    Courtney, R
    Pai, S
    Laughlin, M
    Lim, J
    Batra, V
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (09) : 2788 - 2795
  • [29] Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers
    Kunka, RL
    Hussey, EK
    Shaw, S
    Warner, P
    Aubert, B
    Richard, I
    Fowler, PA
    Pakes, GE
    CEPHALALGIA, 1997, 17 (04) : 532 - 540
  • [30] Pharmacokinetics (PK) and tolerability of single and multiple doses of bosentan, an oral dual endothlein receptor antagonist, in children with pulmonary arterial hypertension
    Barst, RJ
    Ivy, D
    Widlitz, AC
    Moore, K
    Doran, A
    van Giersbergen, P
    Nguyen, N
    Gaitonde, MD
    CIRCULATION, 2002, 106 (19) : 450 - 450